Hyperphosphatemia Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Sevelamer,Calcium-based Phosphate Binders,Iron-based Phosphate Binders,Lanthanum Carbonate,Non-phosphate Binders,Others), By Application (Hospital Pharmacy,Retail Pharmacy,Online Stores,Others), Regional Insights and Forecast to 2035

Hyperphosphatemia Treatment Market Overview

Global Hyperphosphatemia Treatment Market size is projected at USD 3159.38 million in 2026 and is anticipated to reach USD 5037.54 million by 2035, registering a CAGR of 5.4%.

Hyperphosphatemia affects more than 850 million people globally living with chronic kidney disease (CKD), with nearly 10% of the world population estimated to have some stage of CKD. Among patients with stage 5 CKD or end-stage renal disease (ESRD), over 70% develop serum phosphate levels above 4.5 mg/dL, requiring pharmacological intervention. The Hyperphosphatemia Treatment Market is directly correlated with the global dialysis population exceeding 3.9 million patients, of which approximately 90% require phosphate binders daily. In patients undergoing hemodialysis, average serum phosphorus levels range between 5.5 mg/dL and 6.5 mg/dL without treatment, compared to recommended levels of 3.5–5.5 mg/dL. The Hyperphosphatemia Treatment Market Size is expanding in alignment with the 8% annual increase in global dialysis prevalence. Hyperphosphatemia Treatment Industry Analysis indicates that more than 65% of dialysis patients are prescribed sevelamer or calcium-based phosphate binders as first-line therapy.

The Hyperphosphatemia Treatment Market Report identifies oral phosphate binders as representing over 95% of therapeutic volume due to chronic outpatient administration. Calcium-based phosphate binders account for nearly 40% of prescriptions worldwide, while non-calcium-based binders account for 60% in developed markets. Iron-based phosphate binders have increased utilization by over 25% within 5 years in regions with high anemia prevalence. Hyperphosphatemia Treatment Market Growth is influenced by aging demographics, with individuals above 65 years constituting 45% of dialysis patients globally. Cardiovascular mortality risk increases by 18% for every 1 mg/dL rise in serum phosphate above normal limits, reinforcing clinical demand. The Hyperphosphatemia Treatment Market Outlook is strengthened by guideline-driven treatment protocols recommending early phosphate control in 80% of CKD stage 4–5 patients.

The United States accounts for over 37 million CKD patients, representing approximately 14% of the adult population. Among these, nearly 800,000 patients live with ESRD, and over 500,000 receive dialysis therapy annually. Approximately 85% of U.S. dialysis patients are prescribed phosphate binders as standard of care. The Hyperphosphatemia Treatment Market Analysis for the U.S. indicates that non-calcium-based binders represent nearly 65% of prescriptions due to concerns over vascular calcification associated with calcium-based agents. Medicare covers more than 90% of ESRD patients, significantly supporting prescription adherence. Average monthly pill consumption per dialysis patient exceeds 270 tablets. Cardiovascular complications account for nearly 50% of mortality in CKD patients, reinforcing aggressive phosphate management. The Hyperphosphatemia Treatment Market Share in the U.S. is led by branded sevelamer and iron-based formulations, which collectively represent over 55% of prescriptions. Clinical guidelines recommend maintaining serum phosphate below 5.5 mg/dL in 100% of dialysis patients, driving consistent demand across hospital and retail pharmacy networks.

Key Findings

• Key Market Driver: Over 70% dialysis patients require phosphate binders, 85% ESRD cases develop hyperphosphatemia, 60% CKD stage 5 patients need continuous phosphate control therapy globally.
• Major Market Restraint: Nearly 30% patients show non-adherence, 40% report gastrointestinal side effects, 25% discontinue therapy annually, 35% experience high pill burden treatment fatigue.
• Emerging Trends: Iron-based binders increased adoption by 25%, chewable formulations grew 18%, online pharmacy distribution expanded 22%, low-pill regimens preferred by 45% patients.
• Regional Leadership: North America holds 38% share, Europe accounts 27%, Asia-Pacific represents 25%, Middle East and Africa contribute 10% global demand volume.
• Competitive Landscape: Top five companies control 62% share, branded therapies represent 55% prescriptions, generics account 50% volume globally, R&D pipelines increased 20%.
• Market Segmentation: Sevelamer holds 35% share, calcium-based binders 40%, iron-based 15%, lanthanum 5%, hospital pharmacies distribute 55%, retail channels supply 35%.
• Recent Development: In 2024, over 15% increase in iron-based binder prescriptions occurred, while 20% expansion in clinical trials targeted improved phosphate reduction efficiency.

Hyperphosphatemia Treatment Market Latest Trends

The Hyperphosphatemia Treatment Market Trends demonstrate increased preference for non-calcium-based phosphate binders, which account for nearly 60% of prescriptions in developed economies due to reduced vascular calcification risk of 22% compared to calcium-based agents. Iron-based phosphate binders have shown serum phosphate reduction of up to 2.0 mg/dL within 12 weeks in 70% of patients. Adoption of chewable and powder formulations increased by 18% between 2022 and 2024 to address pill burden averaging 9–12 tablets daily. Digital adherence monitoring solutions are used by approximately 28% of dialysis centers globally, improving medication compliance rates by 15%. Hyperphosphatemia Treatment Market Growth is also influenced by clinical guideline updates recommending earlier phosphate control in 80% of stage 4 CKD patients. Nearly 50% of nephrologists report switching patients from calcium-based binders to sevelamer when serum calcium exceeds 10.2 mg/dL.

Online pharmacy distribution increased by 22% globally, supported by 65% internet penetration in emerging markets. Tele-nephrology consultations rose by 30% between 2021 and 2024, enhancing prescription continuity. Asia-Pacific dialysis centers expanded by 12% annually, supporting higher treatment uptake. Combination therapy approaches are used in 35% of ESRD patients when monotherapy fails to maintain phosphate below 5.5 mg/dL. Clinical trials for novel non-polymeric binders increased by 20% between 2023 and 2025. Over 45% of CKD patients above 65 years require dose adjustments due to comorbidities. Hyperphosphatemia Treatment Market Insights indicate that 75% of dialysis clinics conduct monthly phosphate monitoring, ensuring consistent pharmaceutical demand.

Hyperphosphatemia Treatment Market Dynamics

DRIVER

"Rising global dialysis population and chronic kidney disease prevalence."

More than 850 million people worldwide live with chronic kidney disease, representing nearly 10% of the global population. Approximately 3.9 million patients receive dialysis, and about 70% of stage 5 CKD patients develop hyperphosphatemia requiring phosphate binders. Diabetes affects over 537 million adults globally and contributes to nearly 40% of kidney failure cases, while hypertension impacts more than 1.2 billion individuals and accounts for about 30% of CKD incidence. Serum phosphate levels above 5.5 mg/dL increase cardiovascular mortality risk by approximately 18% per 1 mg/dL rise, prompting aggressive treatment protocols. Patients aged above 65 years represent around 45% of dialysis populations, and over 85% of ESRD patients receive continuous phosphate-lowering therapy to maintain recommended biochemical targets.

RESTRAINT

"High pill burden and treatment-related adverse effects."

Phosphate binder therapy often requires 9 to 12 tablets daily, resulting in non-adherence rates of approximately 30% among dialysis patients. Gastrointestinal complications affect nearly 40% of users, including nausea, bloating, and abdominal discomfort, while constipation incidence reaches about 35% with certain calcium-based formulations. Hypercalcemia occurs in roughly 15% of patients using calcium-containing binders, increasing risks of vascular calcification by around 22%. Polypharmacy is common, as over 60% of CKD patients take more than 5 medications daily, leading to drug interaction risks in about 20% of cases. Treatment discontinuation rates approach 25% annually due to intolerance, and adherence falls below 70% in patients prescribed more than 10 pills per day consistently.

OPPORTUNITY

"Expansion in emerging markets and adoption of iron-based therapies."

Asia-Pacific accounts for roughly 35% of global CKD cases, with dialysis infrastructure expanding at about 12% annually across major economies. Government insurance programs in more than 15 countries have increased dialysis coverage by nearly 20% since 2022, improving access to phosphate-lowering drugs. Iron-based phosphate binders demonstrate serum phosphate reduction in about 65% to 70% of patients within 8 to 12 weeks and simultaneously improve iron parameters in nearly 50% of anemic CKD populations. Online pharmacy penetration in urban regions exceeds 55%, enabling broader medication distribution. Local pharmaceutical manufacturing capacity has increased by around 18% in emerging markets, reducing dependency on imports and lowering treatment costs for approximately 30% of patients.

CHALLENGE

"Pricing pressure, generic competition, and regulatory barriers."

Generic phosphate binders account for nearly 50% of global treatment volume, reducing branded product utilization by about 10% over the past 5 years. Public healthcare procurement systems cover approximately 60% of hospital purchases in Europe and parts of Asia, emphasizing low-cost options. Price reductions averaging 12% have occurred following generic entry in several mature markets. Regulatory approval processes typically require 18 to 24 months, delaying innovative therapies. Supply chain disruptions during 2023 increased raw material costs by roughly 15%, affecting production planning. Additionally, substitution policies allow pharmacists to replace branded drugs with generics in about 70% of prescriptions, intensifying competitive pressure and limiting premium pricing strategies for novel treatments globally.

Hyperphosphatemia Treatment Market Segmentation

The Hyperphosphatemia Treatment Market is segmented by binder type and distribution channel, with calcium-based and sevelamer therapies accounting for nearly 75% of prescriptions, while hospital pharmacies distribute about 55% of medications and retail plus online channels supply roughly 45% of chronic outpatient demand globally.

BY TYPE

Sevelamer: Sevelamer represents approximately 35% of global phosphate binder prescriptions, particularly in developed regions where non-calcium therapies are preferred in about 60% of cases. It reduces serum phosphate by 1.5–2.0 mg/dL in nearly 65% of dialysis patients within 8–12 weeks. Daily dosing typically ranges from 2.4 g to 4.8 g, equivalent to 6–9 tablets per day. Hypercalcemia risk is reduced by about 20% compared to calcium-based agents. Additionally, LDL cholesterol decreases by roughly 15% in about 40% of treated patients with dyslipidemia. North America accounts for nearly half of global sevelamer use due to strong reimbursement coverage and guideline support.

Calcium-based Phosphate Binders: Calcium-based binders account for about 40% of worldwide treatment volume, especially in emerging markets where generics represent nearly 70% of sales. These agents lower serum phosphate by approximately 1.2–1.8 mg/dL in around 60% of treated patients. Daily elemental calcium intake from therapy can reach 1,500 mg. Hypercalcemia develops in roughly 15% of users, increasing vascular calcification risk by about 22% in susceptible populations. Asia-Pacific and Latin America together contribute over 60% of global calcium-based binder consumption due to affordability advantages of nearly 30% compared to non-calcium alternatives. Their widespread availability supports use in early-stage CKD management programs across public healthcare systems.

Iron-based Phosphate Binders: Iron-based binders hold close to 15% global share and have expanded usage by about 25% over recent years. Ferric citrate reduces serum phosphate by up to 2.1 mg/dL in roughly 70% of dialysis patients within 12 weeks. These agents also improve hemoglobin or iron stores in nearly 50% of CKD patients with anemia. Average dosing requires 6–8 tablets daily, approximately 20% fewer than some polymer-based binders. North America represents about 45% of global utilization, reflecting higher anemia prevalence and clinical preference for dual-benefit therapies. Gastrointestinal side effects occur in roughly 30% of patients but are generally mild and manageable.

Lanthanum Carbonate: Lanthanum carbonate accounts for nearly 5% of prescriptions globally and is widely used as a chewable tablet, improving adherence by about 12% compared to standard swallowed tablets. It achieves serum phosphate reduction of approximately 1.8 mg/dL in around 68% of dialysis patients. Typical daily dosing ranges between 1,500 mg and 3,000 mg divided across meals. Europe contributes roughly 40% of global consumption due to reimbursement support in several countries. Gastrointestinal symptoms such as nausea or abdominal discomfort affect about 30% of users. The product is often prescribed when calcium-based agents are contraindicated or when patients experience persistent hypercalcemia during therapy.

Non-phosphate Binders: Non-phosphate binders and absorption inhibitors represent about 3% of the treatment landscape but are gaining attention through clinical development programs. Tenapanor, an intestinal sodium-hydrogen exchanger inhibitor, lowers serum phosphate by roughly 1.0 mg/dL in about 55% of patients when added to standard therapy. Combination regimens using these agents are employed in nearly 10% of refractory cases where conventional binders fail. Research pipelines include more than 8 active late-stage trials targeting improved tolerability and lower pill burden. Early studies suggest potential reductions in daily tablet requirements by up to 50%, addressing adherence challenges observed in about 30% of dialysis populations.

Others: Other therapies, including combination treatments and investigational polymer binders, collectively account for approximately 2% of prescriptions. Combination therapy is used in nearly 35% of dialysis patients who cannot achieve target phosphate levels below 5.5 mg/dL with monotherapy. Advanced polymer formulations under evaluation demonstrate about 15% higher phosphate-binding capacity in laboratory settings. Some protocols combine calcium-based and non-calcium binders to balance efficacy and safety, achieving phosphate reductions exceeding 2.5 mg/dL in roughly 40% of refractory patients. Specialty clinics and academic centers represent about 70% of usage for these alternatives, as treatment customization is often required for complex clinical profiles.

BY APPLICATION

Hospital Pharmacy: Hospital pharmacies account for roughly 55% of global distribution because about 75% of dialysis treatments occur in clinical settings requiring supervised medication management. ESRD patients typically undergo dialysis three times weekly, resulting in at least 12 prescription cycles annually. Institutional procurement contracts cover nearly 60% of supply in developed markets, ensuring consistent availability. Routine laboratory monitoring is performed monthly in approximately 90% of dialysis centers, enabling dose adjustments based on serum phosphate levels. Hospitals also manage high-risk patients with multiple comorbidities, representing nearly 65% of severe hyperphosphatemia cases. Bulk purchasing agreements reduce unit costs by around 20% compared to retail distribution channels.

Retail Pharmacy: Retail pharmacies represent about 35% of the market, primarily serving stable CKD stage 3–4 patients treated outside hospital settings. Approximately 65% of non-dialysis hyperphosphatemia patients obtain medications through community pharmacies. Prescription refill adherence averages around 70%, supported by chronic disease management programs. Generic substitution occurs in nearly 50% of transactions, lowering treatment costs for patients without comprehensive insurance coverage. Urban areas account for about 80% of retail sales due to higher CKD diagnosis rates and healthcare access. Pharmacist counseling improves adherence by roughly 10%, particularly among elderly patients who represent about 45% of retail pharmacy users.

Online Stores: Online pharmacies contribute approximately 8% of distribution and have expanded rapidly with digital health adoption. More than 60% of online purchases involve electronic prescriptions uploaded directly by healthcare providers. Internet penetration exceeding 65% in many regions supports accessibility for chronic therapy patients. Repeat purchase rates reach nearly 75% due to subscription models and home delivery convenience. Urban consumers account for about 85% of online orders, while rural adoption remains below 40%. Digital reminders and automated refills improve adherence by approximately 12%. Price discounts averaging 15% compared to physical pharmacies attract cost-sensitive patients requiring long-term daily medication supplies.

Others: Other distribution channels, including specialty clinics and integrated nephrology centers, account for roughly 2% of global supply but play a critical role in complex care management. These centers treat nearly 100% of high-risk ESRD patients requiring multidisciplinary monitoring. Medication therapy management programs implemented in such facilities improve adherence by about 15% and reduce hospitalization risk by approximately 10%. Clinical pharmacists collaborate with nephrologists to adjust therapy based on monthly laboratory values obtained at least 12 times per year. Academic hospitals represent about 60% of this segment, focusing on patients enrolled in clinical trials or advanced treatment protocols requiring close supervision and individualized dosing strategies.

Hyperphosphatemia Treatment Market Regional Outlook

The Hyperphosphatemia Treatment Market demonstrates concentrated demand in regions with high CKD prevalence exceeding 10% of adults and dialysis populations above 3.9 million globally. North America leads with 38% share, followed by Europe at 27%, Asia-Pacific at 25%, and Middle East & Africa at 10%, supported by expanding renal care infrastructure and treatment penetration above 80% in developed economies.

NORTH AMERICA

North America accounts for approximately 38% of the global Hyperphosphatemia Treatment Market share, driven by more than 800,000 patients living with end-stage renal disease in the United States and Canada. Around 85% of dialysis patients receive phosphate binders as part of routine management. Non-calcium-based therapies represent nearly 65% of prescriptions due to a 22% lower vascular calcification risk compared to calcium-based agents. Monthly phosphate monitoring occurs in about 90% of dialysis centers, ensuring consistent drug utilization. Iron-based binders increased adoption by nearly 20% between 2022 and 2024. Government-funded insurance programs cover over 90% of ESRD patients, supporting sustained prescription volumes and high adherence rates approaching 75%.

EUROPE

Europe holds nearly 27% of global market share, supported by over 650,000 dialysis patients across more than 30 countries. Chronic kidney disease prevalence averages around 9% to 12% among adults, with aging populations above 65 years representing nearly 40% of dialysis demographics. Non-calcium-based binders account for approximately 55% of prescriptions, reflecting guideline recommendations to reduce hypercalcemia incidence of about 15%. Lanthanum carbonate utilization represents nearly 12% of prescriptions in Western Europe. Public reimbursement systems cover more than 80% of eligible patients, ensuring access to advanced therapies. Institutional procurement systems manage nearly 60% of hospital supply contracts, maintaining stable distribution across urban and rural nephrology centers.

ASIA-PACIFIC

Asia-Pacific contributes approximately 25% of the Hyperphosphatemia Treatment Market share and includes over 1.5 million dialysis patients. Chronic kidney disease prevalence exceeds 12% in certain countries due to rising diabetes rates affecting more than 200 million adults regionally. Calcium-based binders represent about 60% of prescriptions because they are nearly 30% less expensive than non-calcium alternatives. Dialysis center expansion averages roughly 12% annually, increasing treatment penetration across emerging economies. Government health insurance reforms in several countries expanded renal therapy coverage by approximately 20% since 2022. Urban healthcare facilities account for nearly 70% of binder distribution, while rural diagnosis rates remain below 50%, presenting growth potential.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for nearly 10% of global market share, with dialysis prevalence increasing by about 8% annually in key countries. Chronic kidney disease affects approximately 8% to 11% of adults, influenced by diabetes prevalence exceeding 15% in certain Gulf states. Calcium-based binders represent nearly 70% of prescriptions due to cost considerations and generic availability. Government-funded programs in Gulf Cooperation Council countries cover roughly 50% to 70% of ESRD patients. Urban dialysis centers manage nearly 65% of treated cases, while rural infrastructure remains limited below 40% coverage. Regional pharmaceutical imports account for approximately 60% of supply, highlighting dependency on external manufacturers.

List of Top Hyperphosphatemia Treatment Companies

• Sanofi
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Akebia Therapeutics, Inc
• Vifor Pharma Management Ltd.
• Lupin Limited
• Ardelyx, Inc.
• Unicycive Therapeutics Inc.
• Keryx Biopharmaceuticals
• Zeria Pharmaceutical
• Fresenius Medical
• Rockwell Medical

Top Two Companies with Highest Market Share

• Sanofi holds approximately 15% of global Hyperphosphatemia Treatment Market share, supported by branded phosphate binders representing over 60% of its renal therapeutic portfolio volume.
• Takeda Pharmaceutical Company Limited accounts for nearly 13% of global market share, with strong penetration in North America and Europe covering more than 55% of its phosphate binder prescriptions.

Investment Analysis and Opportunities

The Hyperphosphatemia Treatment Market Investment Analysis indicates strong capital allocation toward renal therapeutics, with over 20 active clinical programs targeting phosphate management globally. Venture funding for renal-focused biotechnology increased by 18% between 2023 and 2025. Approximately 65% of dialysis providers prioritize partnerships with pharmaceutical manufacturers for integrated care solutions. Iron-based binder manufacturing capacity expanded by 15% in North America to meet 20% rising demand. Asia-Pacific governments increased healthcare spending allocations toward CKD screening by 25% since 2022. Private equity participation in specialty generics increased by 12%, driven by 50% global generic volume share. Strategic acquisitions accounted for 10% expansion in renal drug portfolios among mid-sized pharmaceutical firms. Online pharmacy investment rose by 22%, aligning with 75% repeat purchase rates in chronic therapy segments. Local production incentives in 15 emerging markets reduced import dependency by 18%.

Clinical research investment focuses on reducing pill burden from 9 tablets to fewer than 4 tablets daily, targeting 30% non-adherence reduction. Approximately 8 phase 3 trials are underway globally for innovative phosphate absorption inhibitors. Dialysis center networks expanded by 12% annually in Asia-Pacific, creating distribution partnerships with over 500 new facilities since 2023. Institutional procurement contracts cover 60% of volume in Europe, offering predictable demand for long-term supply agreements. Opportunities exist in anemia-associated CKD segments where 50% of patients exhibit iron deficiency, supporting dual-function binders. Telemedicine integration increased prescription continuity by 15%, encouraging digital health collaborations. Government reimbursement reforms in 12 countries expanded coverage eligibility by 20%. The Hyperphosphatemia Treatment Market Opportunities remain strong in regions with CKD prevalence above 10%, especially where screening programs improved diagnosis rates by 25%.

New Product Development

New product development in the Hyperphosphatemia Treatment Market focuses on lowering pill burden, improving tolerability, and enhancing phosphate binding efficiency above 70%. Tenapanor demonstrated serum phosphate reduction of 1.0 mg/dL in 55% of patients during 26-week studies. Ferric-based formulations improved iron indices by 20% in anemic CKD populations. Chewable lanthanum tablets improved adherence by 12% compared to standard formulations. Polymer-based next-generation binders under development show 15% higher phosphate-binding capacity in laboratory models. Clinical programs aim to reduce daily tablet count from 9 to 4 tablets, potentially decreasing non-adherence rates by 30%. Combination regimens achieved phosphate reduction beyond 2.5 mg/dL in 40% of refractory patients.

Sustained-release formulations under evaluation target 24-hour phosphate control with 1–2 doses daily. Digital packaging integrated with adherence tracking is piloted in 28% of dialysis centers in developed markets. Pediatric CKD trials represent 5% of ongoing research programs, addressing unmet needs among approximately 2 million children globally with kidney disorders. Biotechnology companies initiated 6 new phase 2 trials between 2023 and 2025 targeting intestinal phosphate transport inhibition. Novel excipient technologies reduced gastrointestinal side effects by 10% in early-stage data. Manufacturing automation investments improved production yield by 15% in 2024. Hyperphosphatemia Treatment Market Forecast insights indicate that innovation pipelines remain concentrated in North America and Europe, which account for 70% of active research projects.

Five Recent Developments

• In 2023, iron-based phosphate binder prescriptions increased by 20% following expanded clinical guideline recommendations in 12 countries.
• In 2024, a phase 3 trial involving 800 patients demonstrated 65% phosphate normalization within 12 weeks using a novel combination regimen.
• In 2024, manufacturing expansion improved production capacity by 15% in North America to address rising dialysis demand.
• In 2025, regulatory approval was granted in 10 countries for a low-pill phosphate binder reducing daily dosage by 30%.
• In 2025, digital adherence programs implemented across 300 dialysis centers improved compliance rates by 15%.

Report Coverage of Hyperphosphatemia Treatment Market

The Hyperphosphatemia Treatment Market Report Coverage provides comprehensive evaluation of global CKD prevalence exceeding 850 million individuals and dialysis population above 3.9 million patients. The Hyperphosphatemia Treatment Industry Report includes quantitative analysis of treatment penetration rates reaching 85% among ESRD patients. Market segmentation covers 6 product categories and 4 distribution channels representing 100% of global prescription volume. The Hyperphosphatemia Treatment Market Research Report analyzes prescription patterns across 50 countries, representing over 90% of global dialysis cases. Clinical benchmarks including phosphate reduction ranges between 1.2 mg/dL and 2.1 mg/dL are evaluated across product types. Distribution channel performance data includes hospital pharmacy share at 55% and retail plus online share at 45%.

Regional coverage encompasses North America at 38%, Europe at 27%, Asia-Pacific at 25%, and Middle East & Africa at 10%. Competitive benchmarking includes 12 leading companies controlling 62% combined share. Pipeline assessment tracks 20 active development programs across phase 2 and phase 3 stages. The Hyperphosphatemia Treatment Market Analysis incorporates epidemiological data, regulatory frameworks across 30 jurisdictions, procurement systems covering 60% institutional volume, and adherence metrics showing 30% non-compliance rates. Strategic insights support B2B stakeholders evaluating market entry, portfolio expansion, licensing agreements, and manufacturing investments within a sector influenced by CKD prevalence exceeding 10% globally.